Evaluation of the Efficacy of Acupuncture for Irritable Bowel Syndrome with predominant Diarrhea (IBS-D)

注册号:

Registration number:

ITMCTR2000003247

最近更新日期:

Date of Last Refreshed on:

2020-04-27

注册时间:

Date of Registration:

2020-04-27

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

针刺治疗腹泻型肠易激综合征的临床疗效评价研究

Public title:

Evaluation of the Efficacy of Acupuncture for Irritable Bowel Syndrome with predominant Diarrhea (IBS-D)

注册题目简写:

English Acronym:

研究课题的正式科学名称:

针刺治疗腹泻型肠易激综合征的临床疗效评价研究

Scientific title:

Evaluation of the Efficacy of Acupuncture for Irritable Bowel Syndrome with predominant Diarrhea (IBS-D)

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2000032382 ; ChiMCTR2000003247

申请注册联系人:

李珊珊

研究负责人:

李珊珊

Applicant:

Shanshan Li

Study leader:

Shanshan Li

申请注册联系人电话:

Applicant telephone:

+86 13521739047

研究负责人电话:

Study leader's telephone:

+86 13521739047

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

lishanshan722@126.com

研究负责人电子邮件:

Study leader's E-mail:

lishanshan722@126.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

中国北京市西城区北线阁5号广安门医院

研究负责人通讯地址:

中国北京市西城区北线阁5号广安门医院

Applicant address:

5 Bei-Xian-Ge Street, Xicheng District, Beijing, China

Study leader's address:

5 Bei-Xian-Ge Street, Xicheng District, Beijing, China

申请注册联系人邮政编码:

Applicant postcode:

100053

研究负责人邮政编码:

Study leader's postcode:

100053

申请人所在单位:

中国中医科学院广安门医院

Applicant's institution:

Guang'anmen Hospital, China Academy of Chinese Medical Sciences

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2019-096-KY-01

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

中国中医科学院广安门医院伦理委员会

Name of the ethic committee:

the Ethics Committee of Guang'anmen Hospital, China Academy of Chinese Medical Sciences

伦理委员会批准日期:

Date of approved by ethic committee:

2019/6/18 0:00:00

伦理委员会联系人:

乔洁

Contact Name of the ethic committee:

Jie Qiao

伦理委员会联系地址:

中国北京市西城区北线阁5号广安门医院

Contact Address of the ethic committee:

Guang'anmen Hospital, 5 Bei-Xian-Ge Street, Xicheng District, Beijing, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

gamhec@126.com

研究实施负责(组长)单位:

中国中医科学院广安门医院

Primary sponsor:

Guang'anmen Hospital, China Academy of Chinese Medical Sciences

研究实施负责(组长)单位地址:

中国北京市西城区北线阁5号广安门医院

Primary sponsor's address:

5 Bei-Xian-Ge Street, Xicheng District, Beijing, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京市

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

中国中医科学院广安门医院

具体地址:

中国北京市西城区北线阁5号广安门医院

Institution
hospital:

Guang'anmen Hospital, China Academy of Chinese Medical Sciences

Address:

5 Bei-Xian-Ge Street, Xicheng District

经费或物资来源:

中国中医科学院广安门医院

Source(s) of funding:

Guang'anmen Hospital, China Academy of Chinese Medical Sciences

研究疾病:

腹泻型肠易激综合症

研究疾病代码:

Target disease:

Irritable Bowel Syndrome with predominant Diarrhea (IBS-D)

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

评价针刺治疗改善腹泻型肠易激综合征患者的症状、生活质量疗效及安全性,观察记录不良反应与不良事件

Objectives of Study:

This study is to evaluate the efficacy of acupuncture on symptom relief for the diarrhea predominant irritable bowel syndrome patient population. The adverse effects are also monitored for the evaluation of patient safety.

药物成份或治疗方案详述:

针刺组: 针刺经穴:使用华佗牌针灸针(苏州医疗用品厂有限公司)针刺治疗穴位,模仿假针具使用特制的无菌聚乙烯环状泡沫垫敷于皮肤,内径5mm,外径10mm,高5mm,底面粘有双面胶带用于固定,针灸针穿过中间孔刺入皮肤。取穴方案:基础穴+辨证取穴,基础穴:天枢、中脘、足三里、上巨虚、三阴交。随证选穴:肝郁脾虚:百会、印堂、合谷、太冲,脾虚湿盛:公孙、丰隆、章门、阴陵泉,脾肾阳虚:关元、太白、太溪、然谷,脾胃湿热:内庭、阴陵泉、下廉、解溪,如肝郁脾虚之情绪障碍失眠者可电针刺百会、印堂穴。每周治疗3次,治疗8周,共治疗24次,在治疗结束后第12周随访。 对照组: 假针刺非穴:使用顶端无针尖的特制安慰针0.30mm*25mm(苏州医疗用品厂有限公司),安慰针由针柄,针身,钝头针尖以及无菌聚乙烯圆柱形泡沫垫组成,底面直径10mm,高5mm,底面粘有双面胶带用以固定针体。假穴选用非穴点,非穴点为经穴旁开3cm,钝头针不刺入皮肤,模拟针刺组操作及留针时间,治疗频次和总次数同针刺组。每周治疗3次,治疗8周,共治疗24次,在治疗结束后第12周随访。

Description for medicine or protocol of treatment in detail:

The acupuncture group Patients receive acupuncture therapy at acupoints. A sterile polyethylene annulus foam pad (dimension 5mmx10mmx5mm) is applied on the skin on the acupoints to be studied. The acupuncture needles (Hwato brand, manufactured by Suzhou Medical Appliance Factory) will be applied through the pads and penetrate the skin into the acupoints.The obligatory acupoints include the following, ST25 (Tianshu), RN12(zhongwan), ST36(zusanli), ST37(shangjuxu), and SP6(sanyinjiao), which are chosen based on literature review and the consensus of acupuncture experts in Guanganmen hospital. More acupoints can be added onto the treatment in accordance with the patient syndromes:1. Liver depression and spleen deficiency: DU20(baihui), EX-HN3(yintang), LI4(hegu), LR3(taichong); 2. Damp abundance due to spleen asthenia: SP4(gongsun), ST40(fenglong), LR13(zhangmen), SP9(yinlingquan); 3.spleen and kidney yang deficiency: RN4(guanyuan), SP3(taibai), KI3(taixi), KI2(rangu); 4. spleen-stomach damp-heat: ST44(neiting), SP9(yinlingquan), LI8(xialian), ST41(jiexi). Continuous electrical pulse at 6-8 Hz on acupoints DU20(baihui) and EX-HN3(yintang) can be used to treat for IBS-D patients with insomnia of liver depression and spleen deficiency syndrome. Patients receive treatment three times a week for eight weeks. The needle retention time is 30 minutes for each treatment. Patient will return for follow-up in 12 weeks after the completion of eight-week regimen. The control group The placebo needle has a blunt tip which does not penetrate skin and it is used together with the sterile polyethylene cylindrical foam pad (dimension 5mmx10mm). Patients in the control group will receive sham acupuncture treatment at non-acupoints (ambient points 3cm from the acupoint). The needle retention time is the same as the acupuncture group; as well as the treatment regimen and follow-up time.

纳入标准:

①符合腹泻型肠易激综合征诊断标准,同时满足:中文版IBS-SSS量表>75分,粪便常规及培养(≥3次)显示阴性,便隐血试验显示阴性; ②年龄18-65岁; ③签署知情同意书。

Inclusion criteria

1. Patients symptoms meet the ROME-IV criteria for IBS-D while also satisfying the IBS-SSS scale (Chinese version) is greater than 75, the fecal occult blood test must be negative, and the fecal routine test and culture are both negative not less than three times; 2. Patients aged 18 to 65 years old with the capacity to consent for participation.

排除标准:

①年龄>65岁,近期内体重减轻4-5kg以上,有血便、反复发热、肿瘤等病史及其他肠道感染或非感染性疾病,如炎症性肠病、缺血性肠病、肠息肉、功能性腹泻等; ②患有严重的心、肝、肾脏、造血系统疾病、全身营养状况不良、接受过肛门直肠手术的患者; ③在过去30天内曾用过针灸治疗的患者,或过去2周内接受药物治疗的患者; ④怀孕或哺乳期妇女; ⑤3个月之内参加过其他临床试验者。 凡符合上述任意1项者,予以排除。

Exclusion criteria:

The patients who meet either of the conditions listed below will be excluded from the study. 1. The age is below 18 or above 65. The weight loss is greater than 5 kilograms within the last three months. Patients previous medical history is significant of fecal blood, recurrent fever, tumor, and/or other gastrointestinal diseases such as inflammatory bowel disease, polyps, ischemic bowel disease, or functional diarrhea; 2. Patients have severe cardiac, hepatic, renal, and/or hematologic diseases. Patients are malnutrition. Patient should not have surgical history of anorectal procedures; 3. Patients who have received acupuncture therapy within the last thirty days or are on pharmaceutical therapy within the last two weeks are also not included in the study; 4. The females who are pregnant, breast-feeding, and/or not on contraception are also excluded; 5. The patients who participate in other studies in the last three months are also excluded.

研究实施时间:

Study execute time:

From 2019-06-19

To      2023-03-31

征募观察对象时间:

Recruiting time:

From 2020-05-01

To      2022-12-31

干预措施:

Interventions:

组别:

对照组

样本量:

40

Group:

Control Group

Sample size:

干预措施:

假针刺

干预措施代码:

Intervention:

Sham Acupuncture

Intervention code:

组别:

针刺组

样本量:

40

Group:

Experimental group

Sample size:

干预措施:

针刺

干预措施代码:

Intervention:

Acupuncture

Intervention code:

样本总量 Total sample size : 80

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

中国中医科学院广安门医院

单位级别:

三甲医院

Institution/hospital:

Guang'anmen Hospital,China Academy of Chinese Medical Sciences

Level of the institution:

Tertiary A Hospital

测量指标:

Outcomes:

指标中文名:

满意度评价,以0-4分代表一点都不满意、有点满意、中等满意、较大满意和非常满意

指标类型:

次要指标

Outcome:

The patient satisfaction evaluated on the scale from 0 to 4. The bigger the number, the more satisfied about the treatment.

Type:

Secondary indicator

测量时间点:

第8周

测量方法:

Measure time point of outcome:

week 8

Measure method:

指标中文名:

肠易激综合征生活质量评分

指标类型:

次要指标

Outcome:

the Irritable Bowel Syndrome-Quality of Life Measure (IBS-QOL scale)

Type:

Secondary indicator

测量时间点:

基线,第4,8,20周

测量方法:

Measure time point of outcome:

baseline, week 4,8,20

Measure method:

指标中文名:

肠易激综合征病情严重程度量表总分和各项评分较基线变化值

指标类型:

次要指标

Outcome:

the change of IBS-SSS comprehensive scale and individual index compared with baseline

Type:

Secondary indicator

测量时间点:

第4周,8周,20周

测量方法:

Measure time point of outcome:

week 4, 8, 20

Measure method:

指标中文名:

焦虑抑郁自评量表及汉密尔顿焦虑抑郁量表评分

指标类型:

次要指标

Outcome:

SAS, SDS, HAMA and HAMD scores

Type:

Secondary indicator

测量时间点:

基线,第8,20周

测量方法:

Measure time point of outcome:

baseline, week 8, 20

Measure method:

指标中文名:

粪便性状评分

指标类型:

次要指标

Outcome:

the Bristol scale

Type:

Secondary indicator

测量时间点:

基线,第4,8,20周

测量方法:

Measure time point of outcome:

baseline, week 4,8,20

Measure method:

指标中文名:

针刺有效率,定义为治疗后IBS-SSS量表总分较基线改善50分

指标类型:

次要指标

Outcome:

the response rate, defined as the improvement on IBS-SSS scales more than 50 points

Type:

Secondary indicator

测量时间点:

第8周

测量方法:

Measure time point of outcome:

week 8

Measure method:

指标中文名:

使用止泻、解痉药物情况及药物剂量、频次变化

指标类型:

次要指标

Outcome:

Evaluation of the use of other interventions, such as antidiarrheal, antispasmodics, and their frequency and dose.

Type:

Secondary indicator

测量时间点:

基线,第8,20周

测量方法:

Measure time point of outcome:

baseline, week 8, 20

Measure method:

指标中文名:

肠易激综合征病情严重程度量表总分较基线的变化值

指标类型:

主要指标

Outcome:

the change of IBS-SSS comprehensive scale compared with baseline

Type:

Primary indicator

测量时间点:

第8周

测量方法:

Measure time point of outcome:

week 8

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 18
Min age years
最大 65
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

随机由中国医学科学院广安门医院临床研究规范办公室(GCP)执行。使用9.1.3版本SAS软件(SAS Institute,Cary,NC,USA)产生随机区组序列,区组数为4。

Randomization Procedure (please state who generates the random number sequence and by what method):

Randomization is performed by the Good Clinical Practice (GCP) office of Guang’anmen Hospital of the China Academy of Chinese Medical Sciences. Statistics Analysis System software version 9.1.3 (SAS Institute, Cary, NC, USA) is used to generate the random allocation sequence with a block of four.

盲法:

患者、随访评估者和统计人员被盲治疗分组(被盲的电话回访评估),针灸操作人员不被盲。

Blinding:

Patients, evaluators and statisticians are blinded (blinded telephone interviewers)with regard to the acupuncture treatment administered. The acupuncturists can not be blinded.

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2023年9月30日,中国临床试验注册中心网站,http://www.medresman.org/

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

September 30,2023, Chinese Clinical Trial Registry, http://www.medresman.org/

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

在试验开始之前,本研究所有的成员在研究启动后均需参加培训,培训内容主要包括:患者纳入、量表评估、针刺治疗、病例报告表的填写和数据管理等。在每个评估时点由不知晓分组的评价者进行随访,将患者的数据记录在病例报告表中。由2名课题组研究生进行数据双录入并整理成excel文件,交由专门的统计人员进行统计分析。数据监查:本课题组的研究生定期进行监查。稽查由课题组以外的第三方人员稽查试验方案的执行情况。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Prior to the clinical trial, the staff members are required to participate in the training and its content includes the following: case screening, scale evaluation, acupuncture manipulation, patient charting, and data management. There will be blind assessors to follow up and chart the patient progress at the evaluation points. Two students from our research group will enter the data into spreadsheet separately and verify the content. Then, these data will be analyzed by statisticians. All the data will be monitored by the students while the trail will be audited by a third party who does not participate in the trial.

数据管理委员会:

Data Managemen Committee:

暂未确定

Not yet

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above